Stock Ratings / Health Care / IMMX / financials

ANL (52) LXRX (39) ABUS (22) BCAX (45) ⌘ Pro Terminal →

Immix Biopharma Inc. (IMMX) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Q: Is IMMX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Immix Biopharma Inc. (NASDAQ: IMMX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $7.98 (-1.78% 1D, market cap $661.6M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IMMX ranks #864 in composite RQD confidence.

Q: How does IMMX compare to ANL and LXRX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IMMX carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ANL (Adlai Nortye Group Ltd.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $662.0M) and LXRX (Lexicon Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -31.5%, cap $658.5M). Among the 5-stock peer group, IMMX leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for IMMX?

Per IMMX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001873835), Immix Biopharma Inc. generated $0 in revenue, -$29.4M in net income, and -$24.7M in free cash flow against $104.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is IMMX trading relative to its 50-day, 200-day, and 52-week technical levels?

IMMX last traded at $7.98 (-1.78% on volume of 1,073,810 shares), positioning the stock -27.59% below its 50-day simple moving average ($11.02) and -15.82% below its 200-day simple moving average ($9.48). Across its 52-week range of $2.85 to $15.10, IMMX sits at the 41.9% percentile with a 14-day RSI of 30.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($6.98 to $8.98).

Q: How profitable is Immix Biopharma Inc. (IMMX)?

In FY 2025 (10-K), IMMX converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

$7.98 -1.78% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $7.94

Immix Biopharma Inc. (IMMX) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $661.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $7.94 (-0.51%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (33/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.9% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-11.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for IMMX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (33/100 Composite)

🔍 WHY IMMX SCORES 33/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Macro Regime Fit+8/20 pts (24% of score)

FRED Regime × Technicals: 42% of 52W Range • RSI-14 at 30.3 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$9.46-15.6% Next Q

Q2 (-2Q)

Grade E$7.98+2.1% Next Q

Q3 (-1Q)

Grade E$8.15-2.1% Next Q

Current

Grade E$7.98-8.9% Hist 90D α

Trajectory: D (41) → E (33)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a IMMX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While IMMX currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.02) and Max Pain ($8.38) forces dealer call-delta covering toward $15.86.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $IMMX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “IMMX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 33%NO 67%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How IMMX Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $4.00B

FY24

Rev $4.00B

FY25

Rev $4.00B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$4.00B	52%	-0.7%	-$29.4M	-$24.7M	-45%
FY 2024	$4.00B	52%	-0.6%	-$21.6M	-$15.8M	-45%
FY 2023	$4.00B	52%	-0.4%	-$15.4M	-$11.4M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring IMMX)

✓Walkthrough of IMMX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

IMMX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -10.64%🛡️ HOLDING TREND SUPPORT

2026-10-30O $7.86H $8.10L $7.56C $7.98VOL 1.38M

RES: $17.93SUP: $7.60SMA50: $11.02SMA200: $9.48

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

IMMX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 IMMX Butterfly Map → + Track IMMX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on IMMX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for IMMX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for IMMX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (IMMX)

Health Care Rank #864 of 1016 ⚔️ ANL vs IMMX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (IMMX vs. ANL, LXRX, ABUS, BCAX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Immix Biopharma Inc. (IMMX) ranks #864 by composite RQD confidence (33/100, grade E) and #407 by equity capitalization ($661.6M). Within this direct 5-issuer industry benchmark cohort, IMMX leads on earnings valuation at N/A trailing P/E, while LXRX leads on capital efficiency and profitability with -31.5% ROIC and 96.0% gross margin. ANL currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with IMMX at 33/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
IMMX ACTIVE Immix Biopharma Inc.	E	33/100	—	—	-35.0%	-1.78%	$661.6M	Benchmark Subject
ANL Adlai Nortye Group Ltd.	D+	52/100	—	—	—	+0.78%	$662.0M	/anl-vs-immx →
LXRX Lexicon Pharmaceuticals Inc.	D-	39/100	—	96.0%	-31.5%	-0.34%	$658.5M	/lxrx-vs-immx →
ABUS Arbutus Biopharma Corporation	E	22/100	—	—	-35.0%	-0.93%	$656.0M	/abus-vs-immx →
BCAX Bicara Therapeutics Inc.	D	45/100	—	—	-35.0%	-0.31%	$643.9M	/bcax-vs-immx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001873835

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Immix Biopharma Inc. (IMMX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$29.4M, operating cash flow of -$23.9M, and free cash flow of -$24.7M (-56.4% YoY). On the balance sheet, IMMX closed FY2025 with $104.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$29.4M	-$23.9M	-$24.7M	$104.8M	—
FY2024 (FY)	2024-12-31	$0	-$21.6M	-$14.6M	-$15.8M	$22.9M	—
FY2023 (FY)	2023-12-31	$0	-$15.4M	-$11.4M	-$11.4M	—	—

3. IMMX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is IMMX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Immix Biopharma Inc. (NASDAQ: IMMX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $7.98 (-1.78% 1D, market cap $661.6M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, IMMX ranks #864 in composite RQD confidence.

How does IMMX compare to ANL and LXRX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), IMMX carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ANL (Adlai Nortye Group Ltd.) holds a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $662.0M) and LXRX (Lexicon Pharmaceuticals Inc.) posts a D- grade (39/100 RQD, P/E N/A, ROIC -31.5%, cap $658.5M). Among the 5-stock peer group, IMMX leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for IMMX?

Per IMMX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001873835), Immix Biopharma Inc. generated $0 in revenue, -$29.4M in net income, and -$24.7M in free cash flow against $104.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is IMMX trading relative to its 50-day, 200-day, and 52-week technical levels?

IMMX last traded at $7.98 (-1.78% on volume of 1,073,810 shares), positioning the stock -27.59% below its 50-day simple moving average ($11.02) and -15.82% below its 200-day simple moving average ($9.48). Across its 52-week range of $2.85 to $15.10, IMMX sits at the 41.9% percentile with a 14-day RSI of 30.3 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($6.98 to $8.98).

IMMX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Immix Biopharma Inc. (IMMX)?

In FY 2025 (10-K), IMMX converted $4.0B of revenue into a 52% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: IMMX RQD Cockpit IMMX 12M Forecast IMMX Earnings & Move IMMX Dividends & DRIP IMMX Insiders & 13F IMMX Whale Options IMMX Profit Sankey IMMX News & Why